IBOV 172,236.05 ▲ 2.22% IPC MEX 71,866.30 ▲ 0.66% MERVAL 2,848,945 — — USD/BRL5.51▼ 0.03% USD/MXN18.46▼ 0.42% USD/CLP966.96▼ 0.99% USD/COP3,269▲ 4.77% USD/PEN3.41▼ 1.07% USD/ARS1,545▼ 0.02% USD/UYU40.45▲ 0.35% USD/PYG6,450▲ 1.45% USD/BOB11.74▼ 0.59% USD/DOP60.46▲ 2.41% USD/CRC446.56▼ 0.38% USD/GTQ7.64▼ 0.05% USD/HNL26.89▲ 0.02% USD/NIO36.62▲ 2.53% USD/VES897.02▲ 0.07% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.79▲ 2.42% USD/TTD6.72▼ 0.03% EUR/BRL6.19▲ 0.96% BRENT 90.63 ▼ 2.10% WTI 85.11 ▼ 2.00% IRON ORE 161.91 — — COPPER 6.33 ▼ 0.01% GOLD 4,101 ▼ 0.32% SILVER 52.55 ▼ 0.03% SOY 1,196 ▲ 1.14% CORN 441.75 ▲ 0.57% WHEAT 591.25 ▲ 0.55% COFFEE 273.45 ▼ 0.05% SUGAR 18.12 ▼ 0.49% ORANGE JUICE 143.50 ▲ 7.85% COTTON 82.72 ▲ 5.00% COCOA 5,000 ▼ 3.01% BEEF 216.33 ▲ 1.06% CATTLE 328.83 ▲ 2.02% LITHIUM 61.35 ▲ 0.72% PETR4 45.19 ▼ 0.24% VALE3 66.11 ▲ 3.23% ITUB4 41.72 ▲ 2.94% BBDC4 14.68 ▲ 3.38% ABEV3 15.61 ▲ 0.84% BBAS3 17.02 ▼ 0.64% B3SA3 14.85 ▲ 3.20% WEGE3 50.74 ▲ 5.29% PRIO3 59.39 ▼ 1.80% SUZB3 54.20 ▲ 1.50% RENT3 30.83 ▲ 1.78% AZZA3 15.12 ▲ 2.44% CSAN3 2.77 — 0.00% RAIZ4 24.40 ▼ 12.86% PCAR3 2.43 ▲ 1.25% GMAT3 3.83 ▲ 0.79% PSSA3 45.65 ▲ 2.93% CVCB3 0.87 ▲ 3.57% POSI3 3.03 ▼ 1.94% SLCE3 17.30 ▲ 4.15% NATU3 5.71 ▲ 10.44% BRKM5 3.02 ▼ 5.63% RANI3 8.76 ▲ 3.44% CSNA3 4.49 ▲ 1.81% IBOV 172,236.05 ▲ 2.22% IPC MEX 71,866.30 ▲ 0.66% MERVAL 2,848,945 — — USD/BRL 5.51 ▲ 0.05% USD/MXN 18.46 ▼ 0.37% USD/CLP 966.96 ▼ 0.99% USD/COP 3,267 ▲ 4.70% USD/PEN 3.41 ▼ 1.07% USD/ARS 1,545 ▼ 0.02% USD/UYU 40.45 ▲ 0.35% USD/PYG 6,450 ▲ 1.45% USD/BOB 11.74 ▼ 0.59% USD/DOP 60.46 ▲ 2.41% USD/CRC 446.56 ▼ 0.38% USD/GTQ 7.64 ▼ 0.05% USD/HNL 26.89 ▲ 0.02% USD/NIO 36.62 ▲ 2.53% USD/VES 897.02 ▲ 0.07% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.79 ▲ 2.42% USD/TTD 6.72 ▲ 2.10% EUR/BRL 6.19 ▲ 0.99% BRENT 90.63 ▼ 2.10% WTI 85.11 ▼ 2.00% IRON ORE 161.91 — — COPPER 6.33 ▼ 0.01% GOLD 4,101 ▼ 0.32% SILVER 52.55 ▼ 0.03% SOY 1,196 ▲ 1.14% CORN 441.75 ▲ 0.57% WHEAT 591.25 ▲ 0.55% COFFEE 273.45 ▼ 0.05% SUGAR 18.12 ▼ 0.49% ORANGE JUICE 143.50 ▲ 7.85% COTTON 82.72 ▲ 5.00% COCOA 5,000 ▼ 3.01% BEEF 216.33 ▲ 1.06% CATTLE 328.83 ▲ 2.02% LITHIUM 61.35 ▲ 0.72% PETR4 45.19 ▼ 0.24% VALE3 66.11 ▲ 3.23% ITUB4 41.72 ▲ 2.94% BBDC4 14.68 ▲ 3.38% ABEV3 15.61 ▲ 0.84% BBAS3 17.02 ▼ 0.64% B3SA3 14.85 ▲ 3.20% WEGE3 50.74 ▲ 5.29% PRIO3 59.39 ▼ 1.80% SUZB3 54.20 ▲ 1.50% RENT3 30.83 ▲ 1.78% AZZA3 15.12 ▲ 2.44% CSAN3 2.77 — 0.00% RAIZ4 24.40 ▼ 12.86% PCAR3 2.43 ▲ 1.25% GMAT3 3.83 ▲ 0.79% PSSA3 45.65 ▲ 2.93% CVCB3 0.87 ▲ 3.57% POSI3 3.03 ▼ 1.94% SLCE3 17.30 ▲ 4.15% NATU3 5.71 ▲ 10.44% BRKM5 3.02 ▼ 5.63% RANI3 8.76 ▲ 3.44% CSNA3 4.49 ▲ 1.81%
since 2009
Tuesday, November 10, 2026

Covid-19 Brazil

Exclusive Reuters: Mexico focuses vaccine loan request on U.S. stockpile of AstraZeneca doses

By · · 4 min read

RIO DE JANEIRO, BRAZIL – Mexico has asked the United States to share doses of AstraZeneca’s COVID-19 vaccine it has in stock, a senior diplomat said, following up on a request made by President Andres Manuel Lopez Obrador to his counterpart Joe Biden.

Mexico focuses vaccine loan request on U.S. stockpile of AstraZeneca doses
Mexico focuses vaccine loan request on U.S. stockpile of AstraZeneca doses.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Deputy foreign minister for multilateral affairs Martha Delgado said that since the United States had not yet approved the AstraZeneca vaccine it would be a good candidate to offer to Mexico, which has started using it already.

“The possibility exists of being able to have access to some AstraZeneca batches they have,” Delgado said in an interview with Reuters late last week, saying Mexico had made the request in diplomatic conversations since Lopez Obrador spoke to Biden on March 1.

“That vaccine is already authorized in Mexico, but doesn’t have authorization at the moment in the United States,” she said. “They could release it.”

Lopez Obrador asked Biden for a vaccine “loan” during the virtual meeting, after Mexico’s vaccine strategy was knocked off course by a delay in deliveries of the vaccine developed by Pfizer Inc and German partner BioNTech SE.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Trump says deportations "might be too tough"”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

Delgado, who leads Mexico’s diplomatic effort to get vaccine supplies, said the United States had not said whether it would meet the request for AstraZeneca and other vaccines, which she said included those from Moderna Inc and Novavax Inc. The Novavax shot also is not yet authorized in the United States.

A U.S. official, who asked not to be named, said the United States had not agreed to loans or distributions of AstraZeneca vaccines at this time. The person said the United States was not currently in a position to share doses but had already committed to doing so once the supply issue is dealt with domestically.

The U.S. State Department referred inquiries to the Mexican government and vaccine companies. The White House did not immediately respond to requests for comment.

A top U.S. health official told Reuters on Monday that AstraZeneca’s vaccine could be authorized by U.S. regulators in about a month.

The request for AstraZeneca doses is notable because the British-developed drug is the backbone of Mexico’s vaccine strategy, under a shared production deal with Argentina in which Mexico is due to bottle the doses for Latin America other than Brazil, where the vaccine will be manufactured by Fiocruz in Rio de Janeiro.

Delays in the Mexican regulatory process mean the first doses will now not be shipped until the first week of May, Delgado said. Originally, the hope was for production by March, which had already slipped into April.

Delgado said Mexican diplomats also had to overcome delays in delivery of laboratory filters essential for vaccine production from U.S. drugmaker Merck & Co. That situation has not affected the production timeline, she said.

Under the deal with Argentina, the vaccine is produced in bulk in the South American country and shipped to Mexico for bottling. Two shipments of 6 million doses each were sent in January and early February.

Last month, Spanish newspaper El Pais reported that delays at the Mexican laboratory, Liomont, led the Argentine manufacturer to divert the equivalent of 12.8 million doses of vaccine material to a U.S. AstraZeneca bottler.

Delgado said she was not aware of such a diversion, adding that a new shipment from Argentina was due to arrive in Mexico “very soon.”

A senior Argentine government official denied vaccine material was sent to the United States.

“There is no plan of sending them to other places. What did happen is that the U.S. was not exporting some goods that the Mexican lab needed to finish the process,” the official said, requesting anonymity to speak freely.

The delays in U.S. and European vaccines have pushed Mexico toward deals with Russia and China. China offered vaccines quickly, whereas Western countries had prioritized their own populations, leaving developing economies in the lurch, Delgado said.

She said the U.S. situation was understandable given the scale of the pandemic there, adding that the assistance from China would be long remembered. “Mexico will never forget the countries that helped us,” she said.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.